Haemocomplettan P

Haemocomplettan P is a prescription‑only plasma‑derived product that contains human fibrinogen as its active ingredient. It is supplied as a sterile solution for intravenous injection, marketed in the European Union. The preparation is used to replace deficient fibrinogen in patients with congenital or acquired hypofibrinogenemia, helping to support normal clot formation during bleeding episodes or surgical procedures and to aid hemostasis in trauma‑related bleeding under medical supervision.

Haemocomplettan P is indicated for clinical situations where fibrinogen levels are insufficient to maintain effective hemostasis.

- Congenital fibrinogen deficiency (afibrinogenemia, hypofibrinogenemia) requiring replacement therapy. - Acquired hypofibrinogenemia associated with massive hemorrhage, liver disease, or disseminated intravascular coagulation. - Bleeding control during major surgical procedures, including cardiac, hepatic, and orthopedic surgery. - Management of trauma‑related hemorrhage when rapid fibrinogen supplementation is needed. - Support of hemostasis in obstetric bleeding such as postpartum hemorrhage.

Adverse reactions reported with Haemocomplettan P are generally related to its plasma origin and the intravenous route of administration.

Common: - Mild fever or chills during or shortly after infusion. - Transient headache or dizziness. - Nausea or mild gastrointestinal discomfort. - Localized infusion site erythema or swelling.

Serious: - Allergic or anaphylactic reactions, including urticaria, bronchospasm, or hypotension. - Transmission‑related infections (viral or bacterial) despite viral inactivation steps. - Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism.

Before initiating therapy with Haemocomplettan P, clinicians should evaluate patient history and laboratory parameters to minimize risk.

- Verify fibrinogen plasma levels and coagulation profile prior to administration. - Assess for known hypersensitivity to human plasma proteins or any component of the formulation. - Use caution in patients with a history of thromboembolic disease or active clotting disorders. - Monitor for signs of infection, especially in immunocompromised individuals. - Adjust dosage in patients with renal or hepatic impairment as recommended by clinical guidelines. - Avoid use in patients with uncontrolled disseminated intravascular coagulation without specialist input.

Haemocomplettan P may interact with other agents that affect coagulation or immune response, requiring careful management.

Avoid: - Concurrent use of high‑dose anticoagulants (e.g., unfractionated heparin, direct thrombin inhibitors) that could exacerbate bleeding. - Administration with other plasma‑derived clotting factor concentrates without appropriate monitoring.

Use with caution: - Concomitant antiplatelet drugs (e.g., aspirin, clopidogrel) – monitor platelet function and bleeding time. - Immunosuppressive therapies – increased risk of infection; observe for febrile reactions. - Thrombolytic agents – assess risk of paradoxical clot formation.